23andMe, the maker of genetic testing kits for consumers, is partnering with pharmaceutical giant GlaxoSmithKline to develop new drugs. The companies will share both the costs and revenues of the new venture, and GSK also announced a $300 million investment in 23andMe at the same time.

How it works: The idea behind this partnership is to leverage the vast amounts of clinical information 23andMe collects, to help develop products that are highly tailored to specific groups of patients.

23andMe already was selling its data to outside pharma companies, and a spokesperson tells Axios that such agreements will not be affected by the GSK partnership.

More from the 23andMe spox:

"During the four-year agreement with GSK, 23andMe will not engage in new target drug discovery collaborations, but it will continue to work with third parties on other meaningful collaborations. This includes helping with clinical trials and working with researchers on specific communities based on phenotypic data collection to understand patient symptoms, preferences, market research, etc."

Go deeper

What we overlooked in the switch to remote learning

Illustration: Eniola Odetunde/Axios

America’s rapid and urgent transition to online school has come with a host of unforeseen consequences that are only getting worse as it continues into the fall.

The big picture: The issues range from data privacy to plagiarism, and schools are ill-equipped to deal with them, experts say.

Updated 4 hours ago - Politics & Policy

Coronavirus dashboard

Illustration: Sarah Grillo/Axios

  1. Global: Total confirmed cases as of 3 a.m. ET: 30,782,337 — Total deaths: 957,037— Total recoveries: 21,032,539Map.
  2. U.S.: Total confirmed cases as of 3 a.m. ET: 6,764,962 — Total deaths: 199,258 — Total recoveries: 2,577,446 — Total tests: 94,211,463Map.
  3. Politics: In reversal, CDC again recommends coronavirus testing for asymptomatic people.
  4. Health: The dwindling chances of eliminating COVID-19.
  5. World: Guatemalan president tests positive for COVID-19 — The countries painting their pandemic recoveries green.

The positions of key GOP senators on replacing Ruth Bader Ginsburg

Senate Majority Leader Mitch McConnell talks to reporters on Capitol Hill last Thursday. Photo: Chip Somodevilla/Getty Images

With President Trump planning to nominate his third Supreme Court justice nominee by next week, key Republican senators are indicating their stance on replacing the late Justice Ruth Bader Ginsburg just over six weeks out from Election Day.

The big picture: Senate Majority Leader Mitch McConnell (Ky.) has vowed that "Trump’s nominee will receive a vote on the floor of the United States Senate." But Sen. Lisa Murkowski (Alaska) told Alaska Public Media, "I would not vote to confirm a Supreme Court nominee. We are 50 some days away from an election."